Biogen is having a bad day. The investors (the new ones anyway) are feeling the reeling pain of investing into biotech names. This is the truth of reward to risk. When you play in high-beta names as an investor, unfortunately, this can be an outcome. Biogen (Ticker: BIIB) is discontinuing their Alzheimer drug trial. During Phase 3 trial testing, an independent study provided them with little answers and they decided based on the findings they cannot continue the study. What makes this difficult is the pricing of the study was baked into the stock price. Meaning, the stock price is a reflection of future valuations of a company. Since BIIB will not be making any revenue from their Alzheimer drug treatment, traders and investors took profits or took risk off. The second part of this scenario is that BIIB does not have anything that will be a catalyst to the previous pricing of their stock. So now that it is down nearly 30%, there is nothing really to allow the stock to rally back to the higher valuation. This means the stock price is now correcting itself to the current fundamentals and it could mean that BIIB continues lower. This sucks for the investors currently in Biogen. I hope they can recover from this fallout.
Read Similar Articles
Funder Trading Review – Best Prop Trading Firm in 2024?
If you are actively trading in the stock market in 2024, chances are you’ve heard a new buzzword flying around: Prop Trading, short for Proprietary Trading. Whether you’ve tried prop trading or not – or have even heard of it at all – its popularity is quickly growing because it provides everyday traders with a […]
Read ArticleCoach’s Roundtable: FOMC Fallout & Resilient Market Sectors
Every week, the coaches at Prosper Trading Academy offer their insight on some of the most challenging questions covering recent stock market developments, trading tips, and relevant news stories. This week, Scott Bauer, Charlie Moon, and Mike Shorr give their thoughts on why certain stock market sectors are staying resilient amid the FOMC fallout, and […]
Read ArticleCoach’s Roundtable: Making Up Major Losses
Every week, the coaches at Prosper Trading Academy offer their insight on some of the most challenging questions covering recent stock market developments, trading tips, and relevant news stories. This week, Scott Bauer, Charlie Moon, and Mike Shorr cover this week’s CPI report and other future events that could impact the market, along with ways […]
Read ArticleRead Similar Articles
Funder Trading Review – Best Prop Trading Firm in 2024?
If you are actively trading in the stock market in 2024, chances are you’ve heard a new buzzword flying around: Prop Trading, short for Proprietary Trading. Whether you’ve tried prop trading or not – or have even heard of it at all – its popularity is quickly growing because it provides everyday traders with a […]
Read ArticleCoach’s Roundtable: FOMC Fallout & Resilient Market Sectors
Every week, the coaches at Prosper Trading Academy offer their insight on some of the most challenging questions covering recent stock market developments, trading tips, and relevant news stories. This week, Scott Bauer, Charlie Moon, and Mike Shorr give their thoughts on why certain stock market sectors are staying resilient amid the FOMC fallout, and […]
Read ArticleWhat Does Volatility Mean?
Defining Volatility Volatility signifies a security or index price’s degree of variation over time, and is typically associated with price swings in either direction. Volatility often indicates how much risk or uncertainty is tied to the size of changes in an asset’s value. Higher volatility means more risk (the asset’s price can change drastically over […]
Read Article